Back to Journals » Biologics: Targets and Therapy » Volume 6
Review
![Noteworthy comment: Asthma is currently affecting about 235 million people, and is the most common chronic disease in children. It is now well appreciated that asthma is not a simple disease. Reclassifying asthma with identification of sub-phenotypes has great impacts on choosing appropriate therapeutic approaches for improved treatment outcomes. It suggests that proper target should be chosen for individualized therapy. Accordingly, careful patient profiling and selection for clinical trials are extremely important. Moreover, many times, surrogate markers have to be used in clinical practice. This manuscript provided an excellent instruction of how to wisely choose appropriate biomarker(s) for patient classification and proper target(s) for improved therapy.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Lebrikizumab in the personalized management of asthma
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
20,454 | Dovepress* | 15,582+ | 3,423 | 19,005 | |
PubMed Central* | 4,872 | 1,325 | 6,197 | ||
Totals | 20,454 | 4,748 | 25,202 | ||
*Since 14 September 2012 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
30 | 2 | 0 | 0 | 7 | 21 |
View citations on PubMed Central and Google Scholar